GeneMedix plc (“GeneMedix” or “the Company”), the UK biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, has been undertaking a significant number of initiatives to continue developing its biosimilar EPO and to realise the potential of its other programmes.
